Pediatric Dermatology Journal Articles

 
 
  • Atopic Dermatitis and Psychiatric Disorders in Childhood Other than ADHD, which is known to be associated with atopic dermatitis in children, are there other psychiatric conditions or treatments associated with childhood AD?
  • Characteristics of IgG4-Related Disease Across Age Groups A better understanding of the clinical characteristics of IgG4- related disease in different age groups could help guide evaluation and treatment strategies.
  • Evidence-Based Management of Eczema A review of evidence-based recommendations for the treatment of eczema could help inform the clinical management of this skin condition.
  • Tape Strips in Dermatology Research Learn about the technique of tape stripping, a simple, minimally invasive method to access components of the epidermis. What information can be obtained, and for which dermatoses is it best suited?
  • Cutaneous Manifestations of Nutritional Excess This article describes several common cutaneous conditions which may present as manifestations of chronic hyperglycemia and hyperinsulinemia, including acanthosis nigricans and diabetic dermopathy.
  • Erythema Nodosum: A Practical Approach and Diagnostic Algorithm This review presents a diagnostic algorithm to optimize the initial work-up, differential diagnosis, and recommended therapies for erythema nodosum.
  • Spontaneous Resolution of Atopic Dermatitis With Benralizumab This patient experienced spontaneous resolution of atopic dermatitis while participating in a trial of benralizumab for severe asthma, highlighting the potential shared mechanisms of these conditions.
  • A Decade of Next-generation Sequencing in Genodermatoses This review examines the application of next-generation sequencing technologies that have led to novel discoveries of disease-gene associations in inherited skin diseases.
  • Tralokinumab for Atopic Dermatitis: A Promising New Therapy Multiple trials of tralokinumab, an interleukin-13 inhibitor, indicate that it is a promising treatment option for patients with moderate-to-severe atopic dermatitis.
  • Asthma, SARS-CoV-2 and COVID-19 What have we learned about the interaction between asthma and COVID-19? Might asthma medications have an impact on outcomes?
  • Association of COVID-19 With Skin Diseases and Biologics Might underlying skin diseases or exposure to biologics used to treat these conditions increase susceptibility to or mortality from COVID-19?
  • Immune-mediated Diseases and Risk of IBD Are individuals with other immune-mediated diseases at greater risk of developing ulcerative colitis or Crohn's disease?
  • Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis Review current evidence for the use of crisaborole 2% ointment, a topical phosphodiesterase-4 inhibitor, for the treatment of atopic dermatitis.
  • Nicotinamide: Safety & Differences From Niacin Nicotinamide, a form of vitamin B3, is an oral treatment option for actinic keratosis, squamous and basal cell carcinomas, and bullous pemphigoid. How does it relate to niacin--and how is it used?
  • Hormonal Contraceptives and Dermatology Hormonal contraceptives can be beneficial for some dermatologic conditions, while detrimental to others. Review their use in a variety of skin disorders in this paper.
  • Intersection of PCOS and the Gut Microbiome A new review examines the possible association between the gut microbiome and PCOS. Is there a connection?
  • Pediatric Psoriasis Comorbidities This case presentation highlights the many comorbidities that can manifest in children with psoriasis, including juvenile psoriatic arthritis, uveitis, and metabolic disorders.
  • Efficacy of Treatments for PCOS Management in Adolescents Learn more about the safety and efficacy of various treatment options for PCOS in the adolescent population.
  • Selective JAK1 Inhibitors for Treatment of Atopic Dermatitis Review the role of the JAK/STAT pathway in atopic dermatitis, and the pharmacology of the JAK1 inhibitors upadacitinib and abrocitinib, which provide novel oral therapeutic options for this disease.
  • Dermatologic Applications and Safety of JAK Inhibitors Janus kinase inhibitors offer promise for a number of immunologically driven conditions. What are their potential clinical applications in dermatology?